Sanofi-Aventis: French Pharma Giant
Big pharmaceutical stocks in the U.S. have been ailing, but in Europe, the story is different.
Owning big pharma stocks in recent years has pretty much been a prescription for losing money. Product recalls (Vioxx and Bextra, for example), litigation, patent expirations, generic competition, limp new-drug pipelines and unfavorable publicity have buffeted the sector. Stocks such as Pfizer and Eli Lilly have been mostly falling since early 2004.
But over in Europe, pharmaceutical stocks such as Novartis and Roche have been in ruddy good health. Wendell Perkins, co-manager of JohnsonFamily International Value, recommends Sanofi-Aventis, a French pharma giant formed in a 2004 megamerger. Perkins favors Aventis, the world's third largest drugmaker (after Pfizer and GlaxoSmithKline), for its deep, diverse product portfolio and promising pipeline.
Consider: Aventis boasts billion-dollar blockbuster drugs in categories ranging from anti-coagulants (Lovenox and Plavix) and oncology medicines (Taxotene and Eloxatin) to diabetes (Lantus) and insomnia (Ambien) fighters. The company also sells the leading vaccines for afflictions such as influenza and polio. The sources of Aventis's revenues are well balanced geographically: Europe accounts for 40% of sales, the U.S. for 30%, and the rest of the world the remaining 30%.

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Aventis's laboratories have been remarkably fertile. They are currently developing 129 products. Perkins thinks Acomplia, an anti-obesity drug expected to receive approval from the Food and Drug Administration in the second half of this year, will be a new blockbuster.
Sanofi-Aventis is still benefiting from large cost savings wrung out of the merged companies. But unlike many U.S. drug companies, sales growth -- 10% in the first quarter of this year -- has remained robust. Trading at $48 a share, Aventis's American depositary receipts (symbol SNY) sell for 14 times the average of analysts' 2006 earnings estimates.
--Andrew Tanzer
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Four Surprising Signs You’ll Never Retire (and How to Fix Them)
Gearing up to retire? If any of these four signs ring true, you may want to make some changes before you do.
-
Stocks Rise After Trump-Powell Fed Tour: Stock Market Today
Nvidia hit a new all-time high intraday, but another renowned semiconductor name and some less iconic stocks were bigger movers Friday.
-
Are Buffett and Berkshire About to Bail on Kraft Heinz Stock?
Warren Buffett and Berkshire Hathaway own a lot of Kraft Heinz stock, so what happens when they decide to sell KHC?
-
How the Stock Market Performed in the First 6 Months of Trump's Second Term
Six months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Berkshire Hathaway Stock 20 Years Ago, Here's What You'd Have Today
Berkshire Hathaway is a long-time market beater, but the easy money in BRK.B has already been made.
-
If You'd Put $1,000 Into Procter & Gamble Stock 20 Years Ago, Here's What You'd Have Today
Procter & Gamble stock is a dependable dividend grower, but a disappointing long-term holding.
-
My Three-Day Rule for Investing: And If it Applies Now
Stock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Is It Time to Invest in Europe?
Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
Fed Leaves Rates Unchanged: What the Experts Are Saying
Federal Reserve As widely expected, the Federal Open Market Committee took a 'wait-and-see' approach toward borrowing costs.
-
Fed Sees Fewer Rate Cuts in 2025: What the Experts Are Saying
Federal Reserve The Federal Reserve cut interest rates as expected, but the future path of borrowing costs became more opaque.